Title : Osimertinib in advanced EGFR-mutant lung adenocarcinoma with asymptomatic brain metastases: an open-label, 3-arm, phase II pilot study.

Pub. Date : 2022 Jan-Dec

PMID : 35156036






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Background: Osimertinib is selective for both epidermal growth factor receptor (EGFR)-tyrosine-kinase inhibitor (TKI) sensitizing and Thr790Met mutations. osimertinib epidermal growth factor receptor Homo sapiens
2 Background: Osimertinib is selective for both epidermal growth factor receptor (EGFR)-tyrosine-kinase inhibitor (TKI) sensitizing and Thr790Met mutations. osimertinib epidermal growth factor receptor Homo sapiens